A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).
This study has 2 phases: an Induction Phase of up to ~4 Cycles (up to ~12 weeks [cycle =3 weeks]) and a Maintenance Phase of up to ~31 cycles of pembrolizumab (cycle = 3 weeks]); total pembrolizumab treatment duration will be up to ~35 cycles (up to ~2 years). In the Induction Phase, participants receive pembrolizumab plus pemetrexed plus platinum (carboplatin or cisplatin, at the investigator's discretion). In the Maintenance Phase, participants with a partial or complete disease response or with stable disease after completing four cycles of induction therapy and who meet eligibility criteria will be randomly assigned to receive pembrolizumab plus maintenance olaparib OR pembrolizumab plus maintenance pemetrexed. In the Maintenance Phase, participants receive pembrolizumab for up to 31 cycles (cycle = 3 weeks) plus maintenance olaparib OR maintenance pemetrexed until progressive disease (PD), intolerable toxicities, or physician decision.
Qualified participants in each study arm of the maintenance phase (Pembrolizumab plus Olaparib and Pembrolizumab plus Pemetrexed) who complete up to ~35 cycles of pembrolizumab (up to ~2 years [cycle =3 weeks]) may be eligible to receive a second course of pembrolizumab for up to ~17 cycles (up to ~1 additional year). Per protocol, response or progression during the second pembrolizumab course will not be counted towards patient reported outcomes (PROs) or efficacy outcome measures and adverse events during the second pembrolizumab course will not be counted towards safety outcome measures.
Inclusion Criteria:
Have a histologically or cytologically confirmed diagnosis nonsquamous NSCLC.
Have stage IV nonsquamous NSCLC.
Have confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or Proto-oncogene tyrosine-protein kinase (ROS1)-directed therapy is not indicated.
Have measurable disease based on RECIST 1.1.
Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated.
Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase. Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time.
Have a life expectancy of at least 3 months.
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status assessed within 7 days prior to the administration of study intervention.
Have not received prior systemic treatment for their advanced/metastatic NSCLC.
Have adequate organ function.
Male and female participants who are not pregnant and of childbearing potential must follow contraceptive guidance during the treatment period and for 180 days afterwards.
Male participants must refrain from donating sperm, and female participants must refrain from donating eggs to others or freeze/store for her own use during the treatment period and for 180 days afterwards.
Exclusion Criteria:
Merrillville, Indiana 46410, United States
Knoxville, Tennessee 37920, United States
Ciudad Autonoma de Buenos Aires, Buenos Aires C1199ABB, Argentina
Ciudad Autónoma de Buenos Aires, Buenos Aires C1280AEB, Argentina
Porto Alegre, Rio Grande do Sul 90050-170, Brazil
Santa Cruz do Sul, Rio Grande do Sul 96810-110, Brazil
Itajaí, Santa Catarina 88301-220, Brazil
Sao Jose Rio Preto, São Paulo 15080-000, Brazil
Rio de Janeiro, 20231-050, Brazil
São Paulo, 01321-001, Brazil
Rimouski, Quebec G5L 5T1, Canada
Sherbrooke, Quebec J1H 5N4, Canada
Bogotá, Bogota D.C. 111321, Colombia
Koblenz, Rhineland-Palatinate 56068, Germany
Sakai, Osaka 591-8555, Japan
Suntogun, Shizuoka 411-8777, Japan
Palmerston North, Manawatu-Wanganui 4414, New Zealand
Wellington, 6021, New Zealand
Krakow, Lesser Poland Voivodeship 31-202, Poland
Zgorzelec, Lower Silesian Voivodeship 59-900, Poland
Warsaw, Masovian Voivodeship 02-781, Poland
Olsztyn, Warmian-Masurian Voivodeship 10-357, Poland
Moscow, Moscow 115478, Russia
Moscow, Moscow 125284, Russia
Moscow, Moscow 125367, Russia
Nizhny Novgorod, Nizhny Novgorod Oblast 603081, Russia
Omsk, Omsk Oblast 644013, Russia
Saint Petersburg, Sankt-Peterburg 194291, Russia
Saint Petersburg, Sankt-Peterburg 197758, Russia
Saint Petersburg, Sankt-Peterburg 198255, Russia
Kazan', Tatarstan, Respublika 420029, Russia
Suwon, Kyonggi-do 16247, South Korea
Songpa-gu, Seoul 05505, South Korea
Istanbul, 34093, Turkey (Türkiye)
Istanbul, 34722, Turkey (Türkiye)
Dnipro, Dnipropetrovsk Oblast 49102, Ukraine
Ivano-Frankivsk, Ivano-Frankivsk Oblast 76018, Ukraine
Kharkiv, Kharkiv Oblast 61024, Ukraine
Kharkiv, Kharkiv Oblast 61070, Ukraine
Kropyvnitskiy, Kirovohrad Oblast 25006, Ukraine
London, London, City of EC1M 6BQ, United Kingdom